Kineta to Present Poster on Anti-CD27 Agonist Antibody Program at the AACR Annual Meeting 2022

SEATTLE, March 21, 2022 /PRNewswire/ -- Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today that it will present a poster on the company's anti-CD27 agonist antibody program at the American Association for Cancer Research Annual Meeting 2022, taking place April 8-13, 2022 onsite in New Orleans, LA and online. Thierry Guillaudeux, PhD, EVP Research and Development at Kineta, will be presenting new preclinical data on the company's anti-CD27 agonist antibodies in development for the treatment of blood cancers and solid tumors. 

Presentation Details

Title: CD27 a new immuno-oncology target shaping innate and adaptive anti-tumor immune responses
Abstract Number:  5588
Presenter: Thierry Guillaudeux, PhD
Session Type: In-Person and e-Poster Presentation
Session Title: Therapeutic Antibodies 3
Session Time: April 13, 2022 9:00AM – 12:30PM Central Time
Location:  Poster Section 39

CD27 is a clinically validated drug target. It is a member of the TNF receptor superfamily and plays a critical role in T-cell activation by providing a co-stimulatory signal together with its ligand CD70. CD27 is highly expressed on naïve T cells and also provides a co-stimulatory signal for NK cell activation.  Kineta has developed a diverse set of anti-CD27 agonist antibodies. They are fully human monoclonal antibodies (mAbs) that demonstrate low nM binding affinity to CD27 in humans. In preclinical studies, Kineta's selected lead anti-CD27 agonist mAbs induce T cell proliferation, NK activation, and secretion of cytokines involved in T cell priming and recruitment, demonstrating the ability to potentiate new anti-tumor responses. Kineta is in the final stage of lead selection and plans to nominate a clinical candidate in mid-2022.

Kineta is a clinical stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. We have leveraged our expertise in innate immunity to develop first or best-in-class immunotherapies that address the major challenges with current cancer therapy. For more information on Kineta visit our website, www.kinetabio.com, and follow us on Twitter, LinkedIn and Facebook.

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta's plans for pre-clinical and clinical studies, regulatory filings, investor returns, and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta's business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Contact:
Jacques Bouchy
[email protected] 
(206) 378-0400

SOURCE Kineta, Inc.